Summary
Les Laboratoires Servier SAS (Servier) is a research-based pharmaceutical company that researches, develops, manufactures and markets drugs for treating various diseases. The company's portfolio of marketed products treat central nervous system disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, women's health issues, gastrointestinal diseases, hematological disorders, hormonal disorders and others. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs) worldwide. The company also provides contract development and manufacturing services across its global network. Servier sells its products across the world and is headquartered in Suresnes, France.
Les Laboratoires Servier SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Les Laboratoires Servier Acquires Rights Of CX1632 From Cortex Pharma Through Exercise Of Option 16
Venture Financing 17
Ilkos Therapeutics Raises USD14 Million in Seed Financing 17
Partnerships 18
Servier and Transgene Enters into Research Agreement 18
Vernalis and Servier Enter into Discovery Agreement 19
Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 19
Daiichi Sankyo Enters into Distribution Agreement with Servier Canada 20
Spectrum Pharma Enters into Agreement with Servier Canada 21
Crossbeta Biosciences Enters into Research Agreement with Servier Labs 22
Vect-Horus Enters into Agreement with Servier 23
Hybrigenics Extends Research Agreement with Les Laboratoires Servier 23
GeNeuro Enters into Co-Development Agreement with Servier for GnbAC-1 24
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 25
Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 27
Servier Expands Agreement with Novartis 27
Cellectis Enters Into Co-Development Agreement With Servier 28
Institut Curie Extends Research Agreement With Servier To Develop Breast Cancer Treatments 30
Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 31
Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 32
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 32
Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 33
Vernalis And Servier Extend Oncology Drug Discovery Agreement 34
NovAliX And Servier Enter Into Drug Discovery Agreement 35
Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 36
Les Labs Servier Enters Into Research Agreement With Monash Institute 37
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 38
Les Laboratoires Servier Enters Into Research And Development Agreement With Prognomix 39
Les Laboratoires Enters Into Co-Development Agreement With miRagen Therapeutics 39
Hybrigenics Enters Into Research Agreement With Les Laboratoires Servier 41
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 42
Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos 43
Intercept Pharma Enters Into Co-Development Agreement With Servier 44
Servier Enters Into Research Collaboration With Singapore Immunology Network 45
Licensing Agreements 46
Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 46
Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 46
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 48
Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 49
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 49
Servier Exercises Option For Licensing Agreement With MacroGenics For DART Product 51
Servier Enters Into Licensing Agreement With EOS For Antitumor Drug 52
MacroGenics Enters Into Option For Licensing Agreement With Servier For DART Products 53
Servier Extends Licensing Agreement with miRagen 54
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 56
Pfizer Enters into Licensing Agreement Servier for UCART19 57
Servier Exercises Option for Licensing Agreement with Cellectis 58
Horizon Discovery Enters into Licensing Agreement with Servier Lab 59
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 60
Taiho Pharma Enters into Licensing Agreement with Servier 61
Servier and miRagen Extend Licensing Agreement for Cardiovascular Disease 62
Celladon Enters Into Option For Licensing Agreement With Servier 62
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 63
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 64
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 66
Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 67
Asset Transactions 68
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 68
Acquisition 69
Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 69
Les Laboratoires Servier SAS - Key Competitors 71
Key Employees 72
Locations And Subsidiaries 73
Head Office 73
Other Locations & Subsidiaries 73
Recent Developments 75
Clinical Trials 75
Jun 20, 2016: Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) 75
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76
List of Tables
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Les Laboratoires Servier SAS, Deals By Therapy Area, 2011 to YTD 2017 10
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Les Laboratoires Servier Acquires Rights Of CX1632 From Cortex Pharma Through Exercise Of Option 16
Ilkos Therapeutics Raises USD14 Million in Seed Financing 17
Servier and Transgene Enters into Research Agreement 18
Vernalis and Servier Enter into Discovery Agreement 19
Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 19
Daiichi Sankyo Enters into Distribution Agreement with Servier Canada 20
Spectrum Pharma Enters into Agreement with Servier Canada 21
Crossbeta Biosciences Enters into Research Agreement with Servier Labs 22
Vect-Horus Enters into Agreement with Servier 23
Hybrigenics Extends Research Agreement with Les Laboratoires Servier 23
GeNeuro Enters into Co-Development Agreement with Servier for GnbAC-1 24
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 25
Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 27
Servier Expands Agreement with Novartis 27
Cellectis Enters Into Co-Development Agreement With Servier 28
Institut Curie Extends Research Agreement With Servier To Develop Breast Cancer Treatments 30
Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 31
Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 32
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 32
Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 33
Vernalis And Servier Extend Oncology Drug Discovery Agreement 34
NovAliX And Servier Enter Into Drug Discovery Agreement 35
Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 36
Les Labs Servier Enters Into Research Agreement With Monash Institute 37
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 38
Les Laboratoires Servier Enters Into Research And Development Agreement With Prognomix 39
Les Laboratoires Enters Into Co-Development Agreement With miRagen Therapeutics 39
Hybrigenics Enters Into Research Agreement With Les Laboratoires Servier 41
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 42
Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos 43
Intercept Pharma Enters Into Co-Development Agreement With Servier 44
Servier Enters Into Research Collaboration With Singapore Immunology Network 45
Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 46
Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 46
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 48
Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 49
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 49
Servier Exercises Option For Licensing Agreement With MacroGenics For DART Product 51
Servier Enters Into Licensing Agreement With EOS For Antitumor Drug 52
MacroGenics Enters Into Option For Licensing Agreement With Servier For DART Products 53
Servier Extends Licensing Agreement with miRagen 54
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 56
Pfizer Enters into Licensing Agreement Servier for UCART19 57
Servier Exercises Option for Licensing Agreement with Cellectis 58
Horizon Discovery Enters into Licensing Agreement with Servier Lab 59
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 60
Taiho Pharma Enters into Licensing Agreement with Servier 61
Servier and miRagen Extend Licensing Agreement for Cardiovascular Disease 62
Celladon Enters Into Option For Licensing Agreement With Servier 62
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 63
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 64
BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 66
Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 67
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 68
Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 69
Les Laboratoires Servier SAS, Key Competitors 71
Les Laboratoires Servier SAS, Key Employees 72
Les Laboratoires Servier SAS, Subsidiaries 73List of Figures
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
